# US 2014/0271643 A1 · Human notch1 decoys

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271643 A1
- Document ID: US20140271643A1
- Status: Published application
- Kind: A1
- Application number: 14/349,975
- Filed: 2012-10-04
- Published: 2014-09-18
- Earliest claimed: 2011-10-04
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University In the City of New York
- Inventors: Jan Kitajewski; Carrie Shawber; Thaned Kangsamaksin
- Web page: https://patentgrep.com/patent/US20140271643A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- C07K 14/71: for growth factors; for growth regulators
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are Notch1 fusion proteins. These fusion proteins comprise consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of the amino acids in an extracellular domain of a human Notch1 receptor protein and an Fc portion of an antibody. The amino acid sequence of the extracellular domain (ECD) of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of EGF-like repeat 10 and extends at least through the C-terminal amino acid of EGF-like repeat 23. The N-terminal portion of the ECD of the human Notch1 receptor protein may extend up to the C-terminal amino acid of EGF-like repeat 24 or may extend up to the C-terminal amino acid of EGF-like repeat 36. Compositions of these fusion proteins are also provided. Also provided are methods of treating age-related macular degeneration (AMD), diabetic retinopathy and cancer using the fusion proteins described herein.

## Claims

### Claim 1

A fusion protein which comprises consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids in:
(a) an extracellular domain of a human Notch1 receptor protein, followed by
(b) an Fc portion of an antibody,
wherein the extracellular domain of the human Notch1 receptor protein
(i) commences with the amino acid present at the N-terminus of EGF-like repeat 10 and
(ii) extends at least through the C-terminal amino acid of EGF-like repeat 23.

### Claim 2 (depends on 1)

The fusion protein of claim 1, wherein the amino acid sequence of the extracellular domain of the human Notch1 receptor protein extends to a C-terminal amino acid of EGF-like repeat 24.

### Claim 3 (depends on 1)

The fusion protein of claim 1, wherein the amino acid sequence of the extracellular domain of the human Notch1 receptor protein extends to a C-terminal amino acid of EGF-like repeat 36.

### Claim 4 (depends on 1)

The fusion protein of claim 1, wherein the Fc portion of the antibody is the Fc portion of a human antibody.

### Claim 5 (depends on 2)

The fusion protein of claim 2, wherein the sequence of the consecutive amino acids comprises the sequence set forth in SEQ ID NO: 3, commencing with cystine at position 24 and ending with lysine at position 833.

### Claim 6 (depends on 3)

The fusion protein of claim 3, wherein the sequence of the consecutive amino acids comprises the sequence set forth in SEQ ID NO: 5, commencing with cystine at position 24 and ending with lysine at position 1318.

### Claim 7 (depends on 1)

The fusion protein of claim 1, wherein (a) the extracellular domain of the human Notch1 receptor protein is preceded by a signal peptide.

### Claim 8 (depends on 7)

The fusion protein of claim 7, wherein the signal peptide is the signal peptide of human Notch1 protein or the signal peptide of an IgG heavy chain.

### Claim 9 (depends on 8)

The fusion protein of claim 8, wherein the sequence of consecutive amino acids is set forth in SEQ ID NO: 3.

### Claim 10 (depends on 8)

The fusion protein of claim 8, wherein the sequence of consecutive amino acids is set forth in SEQ ID NO: 5.

### Claim 11 (depends on 1)

A composition comprising the fusion protein of claim 1 and a carrier.

### Claim 12 (depends on 11)

A composition of claim 11, wherein the fusion protein is present in an amount effective to inhibit the activity of JAGGED-1 in a pharmaceutically acceptable carrier.

### Claim at position 13

13-23. (canceled)

### Claim 24

A method of treating a subject suffering from age-related macular degeneration (AMD) which comprises administering to the subject a fusion protein in an amount effective to treat the subject's AMD, wherein the fusion protein comprises consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids present in:
(a) an extracellular domain of a human Notch1 receptor protein, followed by
(b) an Fc portion of an antibody,
wherein the extracellular domain of the human Notch1 receptor protein
(i) comprises the amino acid present at the N-terminus of EGF-like repeat 9 and
(ii) extends at least through the C-terminal amino acid of EGF-like repeat 13,
provided that if the N-terminal amino acid is the N-terminal amino acid of EGF-like repeat 1 the C-terminal amino acid is not the C-terminal amino acid of EGF-like repeat 36.

### Claim at position 15

25-26. (canceled)

### Claim 27

A method of treating a subject suffering from diabetic retinopathy which comprises administering to the subject a fusion protein in an amount effective to treat the subject's diabetic retinopathy, wherein the fusion protein comprises consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids present in:
(a) an extracellular domain of a human Notch1 receptor protein, followed by
(b) an Fc portion of an antibody,
wherein the extracellular domain of the human Notch1 receptor protein
(i) comprises the amino acid present at the N-terminus of EGF-like repeat 9 and
(ii) extends at least through the C-terminal amino acid of EGF-like repeat 13,
provided that if the N-terminal amino acid is the N-terminal amino acid of EGF-like repeat 1 the C-terminal amino acid is not the C-terminal amino acid of EGF-like repeat 36.

### Claim at position 17

28-31. (canceled)

### Claim 32

A method of treating a subject suffering from cancer which comprises administering to the subject a fusion protein in an amount effective to treat the subject's cancer, wherein the fusion protein comprises consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids present in:
(a) an extracellular domain of a human Notch1 receptor protein, followed by
(b) an Fc portion of an antibody,
wherein the extracellular domain of the human Notch1 receptor protein
(i) comprises the amino acid present at the N-terminus of EGF-like repeat 9 and
(ii) extends at least through the C-terminal amino acid of EGF-like repeat 13,
provided that if the N-terminal amino acid is the N-terminal amino acid of EGF-like repeat 1 the C-terminal amino acid is not the C-terminal amino acid of EGF-like repeat 36.

### Claim at position 19

33-34. (canceled)

### Claim 35 (depends on 32)

The method of claim 32, wherein the amino acid sequence of the extracellular domain of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of EGF-like repeat 9 and extends to the C-terminal amino acid of EGF-like repeat 23.

### Claim 36 (depends on 32)

The method of claim 32, wherein the amino acid sequence of the extracellular domain of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of EGF-like repeat 9 and extends to the C-terminal amino acid of EGF-like repeat 36.

### Claim 37 (depends on 32)

The method of claim 32, wherein the amino acid sequence of the extracellular domain of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of EGF-like repeat 1 and extends to the C-terminal amino acid of EGF-like repeat 13.

### Claim 38 (depends on 32)

The method of claim 32, wherein the amino acid sequence of the extracellular domain of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of EGF-like repeat 1 and extends to the C-terminal amino acid of EGF-like repeat 24.
